Accelerating research

and development of

new antibiotics and


The Netherlands Antibiotic Development Platform

The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.

NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.

Stay informed on NADP and subscribe to our Update.

NADP Vouchers

An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.

These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.

Latest News

World Bank releases report on antimicrobial resistance

In early October, the World Bank Group released a report on antimicrobial resistance. By looking at several country-based case studies, along with the growing literature on AMR, this report outlines factors both helping and burdening interventions towards controlling AMR, especially in low- and middle-income countries (LMICs).


FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance

The U.S. Food and Drug Administration today approved Fetroja (cefiderocol), an antibacterial drug for treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including kidney infections caused by susceptible Gram-negative microorganisms, who have limited or no alternative treatment options.


Open-access database helps scientists identifying urgently needed new antibiotics

For more than a year now, a publically accessible database is available enabling scientists to share data and insights, learn from past research, and generate new insights into how molecules interact with bacteria. Several pharmaceutical companies (such as Novartis and Achaogen) have uploaded research data from their discontinued candidate antibiotics to the database.


NADP Partners

Supported by

NADP Partners

Supported by